Factors associated with depressive mood at the onset of multiple sclerosis - an analysis of 781 patients of the German NationMS cohort.
CIS
MRI
MS
clinically isolated syndrome
cohort study
depression
neuropsychological symptoms
relapse
sex
smoking
vitamin D
Journal
Therapeutic advances in neurological disorders
ISSN: 1756-2856
Titre abrégé: Ther Adv Neurol Disord
Pays: England
ID NLM: 101480242
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
05
2023
accepted:
07
08
2023
medline:
11
9
2023
pubmed:
11
9
2023
entrez:
11
9
2023
Statut:
epublish
Résumé
Depression has a major impact on the disease burden of multiple sclerosis (MS). Analyses of overlapping MS and depression risk factors [smoking, vitamin D (25-OH-VD) and Epstein-Barr virus (EBV) infection] and sex, age, disease characteristics and neuroimaging features associated with depressive symptoms in early MS are scarce. To assess an association of MS risk factors with depressive symptoms within the German NationMS cohort. Cross-sectional analysis within a multicenter observational study. Baseline data of Mean age was 34.3 years (95% confidence interval: 33.6-35.0). The female-to-male ratio was 2.3:1. At least minimal depressive symptoms (BDI-II > 8) were present in Depressive symptoms need to be assessed in early MS. Patients during relapse seem especially vulnerable to depressive symptoms. Contributing factors such as fatigue, vitamin D deficiency and smoking, could specifically be targeted in future interventions and should be investigated in prospective studies.
Sections du résumé
Background
UNASSIGNED
Depression has a major impact on the disease burden of multiple sclerosis (MS). Analyses of overlapping MS and depression risk factors [smoking, vitamin D (25-OH-VD) and Epstein-Barr virus (EBV) infection] and sex, age, disease characteristics and neuroimaging features associated with depressive symptoms in early MS are scarce.
Objectives
UNASSIGNED
To assess an association of MS risk factors with depressive symptoms within the German NationMS cohort.
Design
UNASSIGNED
Cross-sectional analysis within a multicenter observational study.
Methods
UNASSIGNED
Baseline data of
Results
UNASSIGNED
Mean age was 34.3 years (95% confidence interval: 33.6-35.0). The female-to-male ratio was 2.3:1. At least minimal depressive symptoms (BDI-II > 8) were present in
Conclusion
UNASSIGNED
Depressive symptoms need to be assessed in early MS. Patients during relapse seem especially vulnerable to depressive symptoms. Contributing factors such as fatigue, vitamin D deficiency and smoking, could specifically be targeted in future interventions and should be investigated in prospective studies.
Identifiants
pubmed: 37692259
doi: 10.1177/17562864231197309
pii: 10.1177_17562864231197309
pmc: PMC10492471
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17562864231197309Informations de copyright
© The Author(s), 2023.
Références
Mult Scler. 2014 Feb;20(2):147-55
pubmed: 23836877
Neurol Neuroimmunol Neuroinflamm. 2022 Apr 7;9(3):
pubmed: 35393342
Brain Behav Immun Health. 2022 Jul 06;24:100484
pubmed: 35856061
Mult Scler. 2019 Oct;25(12):1641-1652
pubmed: 30230952
Science. 2022 Jan 21;375(6578):296-301
pubmed: 35025605
Mult Scler. 2020 Apr;26(4):489-500
pubmed: 31456464
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Nutrients. 2023 May 23;15(11):
pubmed: 37299394
Mult Scler. 2007 Nov;13(9):1161-7
pubmed: 17967844
Acta Neuropathol. 2019 Sep;138(3):443-456
pubmed: 31030237
J Neurol Neurosurg Psychiatry. 2012 Dec;83(12):1170-3
pubmed: 22888143
Brain Behav Immun. 2021 May;94:259-265
pubmed: 33571632
Mult Scler. 2003 Jun;9(3):302-6
pubmed: 12814180
J Psychiatr Res. 2011 Feb;45(2):143-9
pubmed: 20630542
Mult Scler. 2019 Apr;25(5):661-668
pubmed: 29532745
Ann Neurol. 2005 Dec;58(6):840-6
pubmed: 16283615
Neuroimage Clin. 2022;36:103203
pubmed: 36179389
Mult Scler Relat Disord. 2021 Jun;51:102904
pubmed: 33780807
Value Health. 2012 Dec;15(8):1029-35
pubmed: 23244804
Med Glas (Zenica). 2016 Feb 1;13(1):44-9
pubmed: 26827706
Ann Neurol. 2018 Jun;83(6):1162-1173
pubmed: 29740872
Proc Natl Acad Sci U S A. 2021 Jan 5;118(1):
pubmed: 33376202
J Neurol Neurosurg Psychiatry. 2020 Jul;91(7):681-686
pubmed: 32371533
Brain Commun. 2022 Jun 13;4(3):fcac152
pubmed: 35770132
Mol Psychiatry. 2023 Apr;28(4):1770-1782
pubmed: 36658334
Neurol Neuroimmunol Neuroinflamm. 2018 Mar 01;5(3):e446
pubmed: 29511705
J Neurol Neurosurg Psychiatry. 2023 Feb;94(2):94-101
pubmed: 36229193
Mult Scler Relat Disord. 2021 Jun;51:102884
pubmed: 33799287
Ann Neurol. 2022 Feb;91(2):192-202
pubmed: 34967456
Mult Scler. 2014 Feb;20(2):192-201
pubmed: 23812284
Mult Scler. 2016 Oct;22(11):1476-1484
pubmed: 26746809
Nutrients. 2021 Sep 24;13(10):
pubmed: 34684344
Mult Scler. 2016 Feb;22(2):239-44
pubmed: 26041798
Neurol Neuroimmunol Neuroinflamm. 2020 Dec 15;8(1):
pubmed: 33465039
Front Neurol. 2022 Jun 17;13:900792
pubmed: 35785351
Adv Clin Exp Med. 2020 Apr;29(4):469-473
pubmed: 32343889
Mult Scler Relat Disord. 2020 Nov;46:102485
pubmed: 32980646
Ther Adv Neurol Disord. 2012 Jan;5(1):13-22
pubmed: 22276073
Brain. 1997 Nov;120 ( Pt 11):2059-69
pubmed: 9397021
Mult Scler. 2000 Jun;6(3):156-62
pubmed: 10871826